MarketResearchNest.com adds “Psoriasis – Pipeline Review, H2 2017” new report to its research database. The report spread across 673 pages with table and figures in it.
Psoriasis – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis – Pipeline Review, H2 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.
Browse full table of contents and data tables at
The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 1, 20, 44, 44, 2, 106, 30 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.
Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
3SBio Inc, AbbVie Inc , Abeome Corp , AbGenomics International Inc , Adello Biologics LLC , Affibody AB ,
Albireo Pharma Inc , Alfacyte Ltd , Allergan Plc , Almirall SA , Alteogen Inc , Amgen Inc , AnaptysBio Inc , ApoPharma Inc , Arbor Pharmaceuticals LLC , Arrien Pharmaceuticals LLC , AstraZeneca Plc , Athenex Inc,
Atlantic Bio Sci LLC, Aurigene Discovery Technologies Ltd , Aurinia Pharmaceuticals Inc ,and many more…
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262579
– The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RandD brief, MoA and other developmental activities.
– The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
More reports on Pipeline Review H2 2017
Estrogen Receptor Beta (ER Beta Or Nuclear Receptor Subfamily 3 Group A Member 2 Or NR3A2 Or ESR2) – Pipeline Review, H2 2017 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Get More Details at https://www.marketresearchnest.com/estrogen-receptor-beta-er-beta-or-nuclear-receptor-subfamily-3-group-a-member-2-or-nr3a2-or-esr2—pipeline-review-h2-2017.html .
MarketResearchNest.com is the most comprehensive collection of market research products and service Psoriasis on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain